Study of the Colonic Carriage of Staphylococcus Aureus in a Prospective Cohort of Patients Undergoing Endoscopic Screening for Digestive Cancer in the University Hospital of Saint-Etienne

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

112 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-02-02

Study Completion Date

2017-10-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Epidemiological study aiming to describe the carriage (nasal, throat, groin, rectal and colonic) of S. aureus in patients without chronic digestive disease who are going to have a colonoscopy for cancer screening. The carriage will be analyzed globally and the similarity of strains isolated from each site will be analyzed using molecular tools. The aim of this study is to better estimate the digestive reservoir of S. aureus to better prevent endogenous infections due to this bacterium.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety of Stool Transplant for Patients With Difficult to Treat C. Difficile Infection

NCT02770326

C. Difficile Infection Cancer

COMPLETED NA

Observational Study on the Diagnostic Evaluation of the Intestinal Microbiota of Patients With COVID-19.

NCT05107245

COVID-19

COMPLETED

Safety and Efficacy of Multiple Daily Dosing of Oral LFF571 in Patients With Moderate Clostridium Difficile Infections

NCT01232595

Moderate Clostridium Difficile Infection

COMPLETED PHASE2

Impact of Probiotic Regimen on Vancomycin Resistant Enterococcus Intestinal Carriage

NCT00437580

Vancomycin Resistant Enterococcus Intestinal Carriage

UNKNOWN PHASE4

Study of the Interactions Between Dientamoba Fragilis and the Gut Microbiota

NCT02534272

Diarrhea

TERMINATED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

STAPHYLOCOCCAL INFECTIONS

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients undergoing a colonoscopy

Staphylococcus aureus carriage is measured in nose, throat, colon, rectum and groin

Group Type EXPERIMENTAL

Staphylococcus aureus carriage

Intervention Type OTHER

nasal, throat, rectal and groin sampling with swabs. Colonic sampling by colonic biopsy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Staphylococcus aureus carriage

nasal, throat, rectal and groin sampling with swabs. Colonic sampling by colonic biopsy

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient affiliated to French social security
* Written consent of the patient
* Patient needing a colonoscopy in the University Hospital of Saint-Etienne, France

Exclusion Criteria

* Patient who decline to participate to the study
* Patient in the incapacity to give consent
* Patient receiving treatment with anticoagulant or antiaggregant platelets
* Patients with a known haemostatic disorder
* Pregnant woman
* Patients with a chronic disease of the gastrointestinal tract
* Patients receiving long-term corticosteroid
* Patient receiving anti staphylococcal antibiotics

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No